ClinicalTrials.gg
CompletedNCT05625334Updated Mar 22, 2024

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

A Phase 1 interventional study of ASA and non-enteric-coated chewable aspirin in Healthy Volunteers, sponsored by Vectura, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Vectura, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing aspirin in Myocardial Infarction — 7 open to participants now, 8 under way, 2 of them phase 3. Aspirin · Myocardial Infarction.

Enrollment
19th of 28
86 · median 400
Started
2022
the only one that year
Phase 1
Only one
of the 29
Registered
24th of 29
by date

Among the 29 studies testing aspirin in Myocardial Infarction, this one is the 19th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1, and was the 24th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

7 of the 29 studies testing aspirin in Myocardial Infarction are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About aspirin

Aspirin: first FDA approval 1950 (PERCODAN), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing aspirin in Myocardial Infarction, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the pharmacodynamics (PD), pharmacokinetics (PK), safety, and tolerability of acetylsalicylic acid powder for oral inhalation (i-ASA) with non-enteric-coated chewable aspirin (C-ASA) in healthy adults by demonstrating bioequivalence.

In the first treatment period, subjects will be randomized to receive either a single dose (100 mg) of I-ASA powder via a Dry Powder Inhaler (DPI) OR a single dose (162 mg) of C-ASA tablets. After a washout period, subjects will be crossed over to receive the other treatment in the second treatment period. All subjects will receive both treatments during the study. Each single dose treatment will be followed by up to 24 hours of serial post-dose PK, PD, and safety/tolerability assessments.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • ASA
  • acetylsalicylic acid
  • cyclooxygenase-1 enzyme
  • oral inhalation
  • inhaled
  • myocardial Infarction
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, ≥18 and ≤55 years of age, with >18.5 and \<32.0 kg/m2 and body weight ≥50.0 kg for males and ≥45.0 kg for females.
  2. Healthy as defined by:

    1. the absence of illness and surgery within 4 weeks prior to dosing.
    2. the absence of clinically significant history of neurological, endocrine, cardiovascular, pulmonary, respiratory, hematological (e.g., thrombocytopenia, neutropenia, bleeding disorders), immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  3. Female subjects of non- must be:

    1. OR
    2. surgically sterile at least 3 months prior to dosing.
  4. Sexually active female subjects of childbearing potential must be willing to use an acceptable method throughout the study as defined in the protocol.
  5. Current non-smoker: no use of tobacco or nicotine products, including any smoking cessation nicotine-containing products (i.e., nicotine replacement therapy [patch, spray, inhaler, gum, lozenge, bupropion SR, clonidine and nortriptyline], e-cigarettes, etc.) for at least 3 months prior to screening.
  6. Agrees to refrain from alcohol consumption for at least 48 hours prior to admission and 48 hours after drug administration of each period.
  7. Able to understand the study procedures and provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal finding at physical examination at screening.
  2. Positive serology test results for , antibody, or antigen and antibody, at screening.
  3. Positive pregnancy test or lactating female subject.
  4. Positive urine drug screen, urine cotinine test, or alcohol breath test.
  5. Known allergic reactions, or to aspirin (ASA), ibuprofen, other NSAIDs, or other related drugs, or to any in the formulation.
  6. Known lack of response (lack of effect) to aspirin in the past.
  7. Clinically significant x-ray, abnormalities or vital signs abnormalities at screening.
  8. Clinically significant abnormal laboratory parameters including:

    1. Hematocrit value ≤ 32%;
    2. count \<142,000 or > 450,000 platelets per µL;
    3. ≥ 3 x ;
    4. AST ≥ 3 x ULN.
  9. Subject with abnormal lung function defined by spirometric testing such that: the post bronchodilator \< 80% of predicted normal value OR FEV1/FVC ratio \< 0.70.
  10. Subject with current asthma defined as post-bronchodilator FEV1 > 12% increase AND > 200 ml absolute increase from pre-bronchodilator values.

Other protocol-defined I/E criteria that apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Arm 1: I-ASA 100mg, then C-ASA 162mg tablet

    Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI. Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA).

    Drug: ASA · Drug: non-enteric-coated chewable aspirin

  • Experimental
    Arm 2: C-ASA 162mg tablet, then I-ASA 100mg

    Treatment B: Single dose of 162 mg chewable non-enteric-coated Aspirin (C-ASA). Treatment A: Single dose of 100 mg ASA powder for oral inhalation (I-ASA) via DPI.

    Drug: ASA · Drug: non-enteric-coated chewable aspirin

Interventions

  • DrugASA

    powder for oral inhalation via a Dry Powder Inhaler (DPI)

  • Drugnon-enteric-coated chewable aspirin

    Orally administered

06

What researchers measure

Primary outcomes

  1. Serum thromboxane B2 (TxB2) serum concentration - Area under the effect curve (AUEC) of the % Change from baseline (CFB) in serum TxB2 concentration (TxB2 suppression)

    Time frame: 24 hours post-dose

Secondary outcomes

  1. Proportion of subjects achieving significant inhibition of platelet aggregation (<550 Aspirin Reaction Units [ARU])

    Time frame: 2 minutes post-dose

  2. TxB2 serum concentration - AUEC of the % CFB in serum TxB2 concentration (TxB2 suppression)

    Time frame: 20 minutes post-dose.

  3. TxB2 serum concentration - AUEC of the % CFB in serum TxB2 concentration (TxB2 suppression)

    Time frame: 30 minutes post-dose

  4. Time to significant inhibition of platelet aggregation (<550 ARU).

    Time frame: assessed up to 24 hours post-dose

  5. Peak plasma concentrations (Cmax) of ASA

    PK endpoints

    Time frame: pre-dose. minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 360, 480, 720 and 1440

  6. Peak plasma concentrations (Cmax) of SA

    PK endpoints

    Time frame: pre-dose. minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 360, 480, 720 and 1440

  7. Area under the plasma concentration versus time curve (AUC0-inf)

    PK endpoints

    Time frame: pre-dose. minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 360, 480, 720 and 1440

  8. Area under the plasma concentration versus time curve (AUC0-t)

    PK endpoints

    Time frame: pre-dose. minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 360, 480, 720 and 1440

  9. Time to peak plasma concentrations (Tmax) of ASA

    PK endpoints

    Time frame: pre-dose. minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 360, 480, 720 and 1440

  10. Time to peak plasma concentrations (Tmax) of SA

    PK endpoints

    Time frame: pre-dose. minutes post-dose: 2, 5, 10, 20, 30, 45, 60, 120, 180, 360, 480, 720 and 1440

  11. Incidence and frequency of Adverse Events.

    Time frame: screening through the 7-day to follow-up period

07

Study locations

2 sites
  • Sinai Hospital
    Baltimore, Maryland 21215, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
08

References and documents

Publications

  • Gurbel PA, Bliden KP, Chaudhary R, Tantry US. First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid. Circulation. 2020 Sep 29;142(13):1305-1307. doi: 10.1161/CIRCULATIONAHA.120.047477. Epub 2020 Sep 28. No abstract available. PubMed 32986482 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Mar 2023, 4 months.

Of 13 phase 1 interventional studies under Myocardial Infarction, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2022
First posted
Nov 22, 2022
StartActual
Oct 14, 2022
Primary completionActual
Mar 9, 2023
CompletionActual
Mar 9, 2023
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05625334
Lead sponsor
Vectura, Inc.
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Nov 22, 2022
Start date
Oct 14, 2022
Primary completion
Mar 9, 2023
Completion
Mar 9, 2023
Last update
Mar 22, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aspirin

Start the discussion